Literature DB >> 13956

Renal failure, drug pharmacokinetics and drug action.

J Fabre, L Balant.   

Abstract

Patients with renal insufficiency often react abnormally to a number of drugs. Small doses that are safe under normal conditions may cause severe and even fatal side-effects. As a consequence, modification of the usual drug dosage of these drugs in required in renal insufficiency. Since the risk of retention concerns only those drugs which are mainly excreted by the kidney, it is possible to establish a mathematical relationship between glomerular filtration rate and the rate of drug elimination. These relationships serve as a basis for the determination of the proper dosage regimen for the individual patient. Such dosage adaptation for intermitten drug administration can be obtained by two methods and a series of compromises between them: (1) increase of the dosage interval without changing the dose, and (2) reduction of the does without changing the frequency of administration. One must however, not only consider inadequate drug elimination but also a number of other factors. Some of these modify the behaviour of the drug, such as hypoalbumineamia, which causes an increase of the unbound portion of the drug; anomalies of the volume of distribution, as found in patients with oedema; metabolic disturbance; alteration of absorption from the gastro-intestinal tract, etc. Other factors are related only indirectly to the pharmacokinetic behaviour of the drug. Frequently, there is an increased sensitivity to the undesirable side-effects of certain drugs in patients with renal insufficiency, causing the level of tolerance to be lowered compared with normal patients. Such an effect probably involves functional or morphological modifications of the drug receptors, or interaction with substance retained in renal insufficiency. Furthermore, drugs may accentuate the consequences of the nephropathy or have increased nephrotoxicity for those with diseased kidneys. It is with these important reservations that a critical analysis of the proposed methods of adapting drug dosage in renal insufficiency is presented. An appendix tabulates the effects of renal insufficiency on the behaviour of 117 drugs. Irrespective of the method used to calculate drug dosage, all patients with renal disease must be monitored closely, particularly for signs of unexpected drug toxicity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 13956     DOI: 10.2165/00003088-197601020-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  59 in total

1.  The blood-cerebrospinal fluid barrier in uremia.

Authors:  R B FREEMAN; M F SHEFF; J F MAHER; G E SCHREINER
Journal:  Ann Intern Med       Date:  1962-02       Impact factor: 25.391

2.  [Synthetic curare-like substances in man].

Authors:  P HUGUENARD
Journal:  Anesth Anal       Date:  1951-06

3.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

4.  Clofibrate, nephrotic syndrome, and histological changes in muscle.

Authors:  M Denizot; J Fabre; D Pometta; E Wildi
Journal:  Lancet       Date:  1973-06-09       Impact factor: 79.321

5.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors:  I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal:  Lancet       Date:  1970-10-17       Impact factor: 79.321

Review 6.  The subcellular basis for the mechanism of inotropic action of cardiac glycosides.

Authors:  K S Lee; W Klaus
Journal:  Pharmacol Rev       Date:  1971-09       Impact factor: 25.468

7.  Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.

Authors:  I Odar-Cederlöf; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

8.  Permeability changes in experimental uremic encephalopathy.

Authors:  R A Fishman
Journal:  Arch Intern Med       Date:  1970-11

Review 9.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Carbohydrate metabolism in uremia: blood glucose response to sulfonylurea.

Authors:  B D Cohen; J A Galloway; R E McMahon; H W Culp; M A Root; K J Henriques
Journal:  Am J Med Sci       Date:  1967-11       Impact factor: 2.378

View more
  47 in total

1.  Stereoselective disposition of flurbiprofen in uraemic patients.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

Review 2.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

3.  [Indications for the determination of plasma concentrations of aminoglycosides].

Authors:  G Hitzenberger
Journal:  Infection       Date:  1977-06       Impact factor: 3.553

4.  Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.

Authors:  C T Ueda; B S Dzindzio
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 5.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 6.  Pharmacokinetics in patients with cardiac failure.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 7.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

8.  The metabolic disposition of flucloxacillin in patients with impaired kidney function.

Authors:  H H Thijssen; J Wolters
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent.

Authors:  U Klotz; P Müller-Seydlitz; P Heimburg
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

10.  The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man.

Authors:  K K Adjepon-Yamoah; G Edwards; A M Breckenridge; M L Orme; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.